461 related articles for article (PubMed ID: 21958949)
1. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
Launer LJ; Miller ME; Williamson JD; Lazar RM; Gerstein HC; Murray AM; Sullivan M; Horowitz KR; Ding J; Marcovina S; Lovato LC; Lovato J; Margolis KL; O'Connor P; Lipkin EW; Hirsch J; Coker L; Maldjian J; Sunshine JL; Truwit C; Davatzikos C; Bryan RN;
Lancet Neurol; 2011 Nov; 10(11):969-77. PubMed ID: 21958949
[TBL] [Abstract][Full Text] [Related]
2. ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.
Murray AM; Hsu FC; Williamson JD; Bryan RN; Gerstein HC; Sullivan MD; Miller ME; Leng I; Lovato LL; Launer LJ;
Diabetologia; 2017 Jan; 60(1):69-80. PubMed ID: 27766347
[TBL] [Abstract][Full Text] [Related]
3. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
[TBL] [Abstract][Full Text] [Related]
4. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.
Rapp SR; Gaussoin SA; Sachs BC; Chelune G; Supiano MA; Lerner AJ; Wadley VG; Wilson VM; Fine LJ; Whittle JC; Auchus AP; Beddhu S; Berlowitz DR; Bress AP; Johnson KC; Krousel-Wood M; Martindale-Adams J; Miller EC; Rifkin DE; Snyder JK; Tamariz L; Wolfgram DF; Cleveland ML; Yang M; Nichols LO; Bryan RN; Reboussin DM; Williamson JD; Pajewski NM;
Lancet Neurol; 2020 Nov; 19(11):899-907. PubMed ID: 33098800
[TBL] [Abstract][Full Text] [Related]
5. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
[TBL] [Abstract][Full Text] [Related]
6. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
Bergenstal RM; Johnson M; Passi R; Bhargava A; Young N; Kruger DF; Bashan E; Bisgaier SG; Isaman DJM; Hodish I
Lancet; 2019 Mar; 393(10176):1138-1148. PubMed ID: 30808512
[TBL] [Abstract][Full Text] [Related]
7. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
8. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
[TBL] [Abstract][Full Text] [Related]
9. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
Reznik Y; Cohen O; Aronson R; Conget I; Runzis S; Castaneda J; Lee SW;
Lancet; 2014 Oct; 384(9950):1265-72. PubMed ID: 24998009
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V;
Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131
[TBL] [Abstract][Full Text] [Related]
11. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.
Williamson JD; Launer LJ; Bryan RN; Coker LH; Lazar RM; Gerstein HC; Murray AM; Sullivan MD; Horowitz KR; Ding J; Marcovina S; Lovato L; Lovato J; Margolis KL; Davatzikos C; Barzilay J; Ginsberg HN; Linz PE; Miller ME;
JAMA Intern Med; 2014 Mar; 174(3):324-33. PubMed ID: 24493100
[TBL] [Abstract][Full Text] [Related]
12. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
[TBL] [Abstract][Full Text] [Related]
13. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
15. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
Gerstein HC; Miller ME; Ismail-Beigi F; Largay J; McDonald C; Lochnan HA; Booth GL;
Lancet; 2014 Nov; 384(9958):1936-41. PubMed ID: 25088437
[TBL] [Abstract][Full Text] [Related]
16. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
18. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
19. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]